Entropy Advances Clinical Trial with Third Patient Dosed in TRP-8803 BED Study
Entropy Neurodynamics Limited (ASX: ENP) has reported continued progress in its clinical-stage Binge Eating Disorder (BED) trial, with the third patient successfully dosed with its IV-infused psilocin therapy, TRP-8803. The patient achieved a full and controlled psychedelic response, reinforcing the therapy’s ability to deliver consistent onset, depth, and duration—key advantages over oral psilocybin. The study aims to recruit 12 patients across two groups, with each participant receiving two doses spaced 14 days apart in combination with supportive care. Cohort 1 dosing is nearing completion, while enrolment for Cohort 2 is already underway. Early clinical observations, including results from the first patient, have demonstrated meaningful improvements across binge eating behaviour, anxiety, depression, and overall wellbeing. These outcomes provide encouraging early validation of TRP-8803’s therapeutic potential, with further clinical data and a larger trial expected to commence in the near term.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Entropy Advances Clinical Trial with Third Patient Dosed in TRP-8803 BED Study
Entropy Neurodynamics Limited (ASX: ENP) has reported continued progress in its clinical-stage Binge Eating Disorder (BED) trial, with the third patient successfully dosed with its IV-infused psilocin therapy, TRP-8803. The patient achieved a full and controlled psychedelic response, reinforcing the therapy’s ability to deliver consistent onset, depth, and duration—key advantages over oral psilocybin. The study aims to recruit 12 patients across two groups, with each participant receiving two doses spaced 14 days apart in combination with supportive care. Cohort 1 dosing is nearing completion, while enrolment for Cohort 2 is already underway. Early clinical observations, including results from the first patient, have demonstrated meaningful improvements across binge eating behaviour, anxiety, depression, and overall wellbeing. These outcomes provide encouraging early validation of TRP-8803’s therapeutic potential, with further clinical data and a larger trial expected to commence in the near term.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au